Search | Clinical Trials Finder

Conditions: Allergic Contact Dermatitis
Interventions: Patch testing; Diagnostic Test
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hiv
Interventions: TelePrEP; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Years to 24 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Infertility
Interventions: CAPA-IVM System, Serial Unstimulated Transvaginal Oocyte Retrieval, ICSI, Blastocyst Culture, PGT-A, Embryo Vitrification/Accumulation, and Single Euploid Embryo Transfer; Device · Procedure
Lead sponsor: Kevin Doody; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bedford, Texas

Conditions: Pharmacogenetic Testing, Elderly, Opioid Use, Pain, Pain, Acute, Pain, Chronic
Interventions: Pharmacogenetic Test; Other
Lead sponsor: Tabula Rasa HealthCare; Industry
Eligibility: 55 Years and older
Enrollment: 2,500 participants
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Type 1 Diabetes
Interventions: Insulin Pump with Continuous Glucose Monitoring; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 7 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 23
States / cities: Little Rock, Arkansas • Palo Alto, California • San Francisco, California + 20 more

Conditions: Uterine Cervical Neoplasms, Uterine Cervical Cancer, Neoplasms, Squamous Cell, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Papilloma
Interventions: BD SurePath Plus Pap test, BD SurePath Pap test, colposcopy with biopsy/ECC, HPV DNA test; Device · Procedure
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 5,859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Osimertinib, Pharmacological Study, Sapanisertib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Tampa, Florida

Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)
Interventions: PRGN-2009, Pembrolizumab, EKG, CT, PET scan, MRI, Biopsy; Biological · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Shwachman-Diamond Syndrome
Interventions: Oral Glucose Tolerance Test, Modified Oral Glucose Tolerance Test, Modified Mixed Meal Tolerance Test, Continuous Glucose Monitor, Food Diary, Medical History Questionnaires; Diagnostic Test · Other · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 3 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant, Recurrent Astrocytoma, IDH-Mutant, Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions: Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Triapine; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 43
States / cities: Duarte, California • Irvine, California • La Jolla, California + 34 more

Conditions: Intrauterine Growth Retardation
Interventions: selective laser photocoagulation of communicating vessels, Expected Management; Procedure · Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Los Angeles, California • Tampa, Florida

Conditions: Healthy
Interventions: Mexican or American foods; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Menopausal Symptoms
Interventions: tamoxifen citrate, gene expression analysis, pharmacogenomic studies, questionnaire administration, quality-of-life assessment; Drug · Genetic · Other + 1 more
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 21 Years to 120 Years · Female only
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 7
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 4 more

Conditions: Point of Care STI Testing
Interventions: Gonorrhea/chlamydia Point-of-Care Testing; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 16 Years to 24 Years
Enrollment: 6,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus, RSV, Rhinovirus
Interventions: Aptitude Medical Systems Respiratory Panel Test; Diagnostic Test
Lead sponsor: Aptitude Medical Systems; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Trussville, Alabama

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • New Haven, Connecticut • Buffalo, New York + 3 more

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy; Procedure · Other · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 75 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2075
U.S. locations: 164
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more

Conditions: Pharmacogenetics, Depressive Disorder, Major, Medication Therapy Management
Interventions: Pharmacogenomic Screening; Other
Lead sponsor: Auburn University; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: G6PD Deficiency
Interventions: SD Biosensor G6PD Analyzer, Pointe Scientific Test Kit, HemoCue System; Diagnostic Test
Lead sponsor: PATH; Other
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Erdafitinib, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment, Questionnaire Administration, Survey Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Years to 39 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Madera, California + 60 more

Conditions: Sepsis, Burn, Inflammation, Burn Infection
Interventions: PSP Monitoring; Device
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Cervical Cancer, Endometrial Cancer, Vaginal Cancer
Interventions: CT or MRI + Blood Test; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Behavior, Risk
Interventions: 3x3 between-subjects experimental exposure; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Patient Experience and Quality of Patch Testing on the Legs vs Back

TelePrEP for At-risk Youth in Colorado

Hormone-free Antral Retrieval for Viable Embryo Storage & Transfer

Pharmacist-led Pharmacogenomic Clinical Service Within the Program of All-inclusive Care for the Elderly

Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM

Intended Use Study of the BD SurePath Plus™ Pap

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Diabetes/ Endocrine Surveillance in SDS

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Randomized Clinical Trial: Expectant Management vs Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation and Absent or Reverse Diastolic Flow in the Umbilical Artery

COMIDAS Comparing Original Mexican Diets and Standard US Diets

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

Point of Care STI Testing

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans

Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Sepsis Biomarker Monitoring in Burn Patients

Pelvic Fractures and Radiation Therapy for Cervical Cancer

Human Laboratory Study of the Effects of Nicotine Product Claims on Appeal, Perceptions, and Use Behavior